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abstract
PURPOSE Somatostatin analogs (SSAs) are recommended for the first-line treatment of most patients with well-
differentiated, gastroenteropancreatic (GEP) neuroendocrine tumors; however, benefit from treatment is
heterogeneous. The aim of the current study was to develop and validate a progression-free survival (PFS)
prediction model in SSA-treated patients.
PATIENTS AND METHODS We extracted data from the Spanish Group of Neuroendocrine and Endocrine Tumors
Registry (R-GETNE). Patient eligibility criteria included GEP primary, Ki-67 of 20% or less, and first-line SSA
monotherapy for advanced disease. An accelerated failure time model was developed to predict PFS, which was
represented as a nomogram and an online calculator. The nomogram was externally validated in an independent
series of consecutive eligible patients (The Christie NHS Foundation Trust, Manchester, United Kingdom).
RESULTSWe recruited 535 patients (R-GETNE, n = 438; Manchester, n = 97). Median PFS and overall survival
in the derivation cohort were 28.7 (95% CI, 23.8 to 31.1) and 85.9 months (95% CI, 71.5 to 96.7 months),
respectively. Nine covariates significantly associated with PFS were primary tumor location, Ki-67 percentage,
neutrophil-to-lymphocyte ratio, alkaline phosphatase, extent of liver involvement, presence of bone and
peritoneal metastases, documented progression status, and the presence of symptoms when initiating SSA. The
GETNE-TRASGU (Treated With Analog of Somatostatin in Gastroenteropancreatic and Unknown Primary NETs)
model demonstrated suitable calibration, as well as fair discrimination ability with a C-index value of 0.714 (95%CI,
0.680 to 0.747) and 0.732 (95% CI, 0.658 to 0.806) in the derivation and validation series, respectively.
CONCLUSION The GETNE-TRASGU evidence-based prognostic tool stratifies patients with GEP neuroendocrine
tumors receiving SSA treatment according to their estimated PFS. This nomogram may be useful when
stratifying patients with neuroendocrine tumors in future trials. Furthermore, it could be a valuable tool for
making treatment decisions in daily clinical practice.
J Clin Oncol 37:2571-2580. © 2019 by American Society of Clinical Oncology
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INTRODUCTION
Gastroenteropancreatic neuroendocrine tumors (GEP-
NETs) are a heterogeneous group of neoplasms that
follow a variable clinical course and are defined by the
WHO 2010 classification into three subgroups on the
basis of proliferation index1; however, within each
category, cases with a different clinical and biologic
behavior continue to coexist.2
Somatostatin analogs (SSAs) are currently the recom-
mended first-line treatment of most patients who are
diagnosed with advanced, well-differentiated GEP-
NETs3,4 as they provide prolonged progression-free
survival (PFS) with an acceptable toxicity profile.
PFS is often used as an outcome measure of patients
with GEP-NETs because it is a surrogate variable for
overall survival (OS).5,6 Despite SSAs being the
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treatment of choice for many patients with GEP-NET,
benefit from treatment—in terms of PFS—is far from ho-
mogenous across the entire spectrum of SSA-treated GEP-
NETs. Several observations support the need to develop
robust multivariable models to predict PFS that are able to
assist clinicians in treatment decisions and investigators in
the design of new treatment strategies. The phase III
CLARINET (Controlled Study of Lanreotide Antiproliferative
Response in Neuroendocrine Tumors) and PROMID
(Prospective, Randomized Study on the Effect of Octreotide
LAR in the Control of Tumor Growth in Patients with
Metastatic Neuroendocrine Midgut Tumors) trials dem-
onstrated the antiproliferative effect of SSAs,7-9 with striking
differences observed in median PFS in both studies. Most
participants in the PROMID trial had a low liver tumor load
and a Ki-67 index of 2% or less (expected to be a population
with less aggressive, slow-growing disease). Despite this,
approximately 25% of participants assigned to SSA in this
study experienced progression before 6 months, which
indicated that treatment was insufficient in that subgroup.
Unfortunately, it was difficult to further characterize this
patient population in univariable survival analyses. In the
CLARINET study, long-acting lanreotide (Somatuline
Autogel; Ipsen, Paris, France) prolonged PFS compared
with placebo. Despite prognosis being notably different
depending on the site of the primary tumor, other predictors
of increased benefit from treatment were not identified.7
Multivariable analyses have established that liver tumor
load, histologic grade, and the site of the primary tumor are
predictive factors for PFS, thus contributing to prognosis
and representing factors to account for when making
treatment decisions.10 However, these and other studies
failed to factor in the additive effect of multiple covariates
that converge in the course of GEP-NETs or were in-
sufficient to make individual predictions of PFS.9,10
Other targeted therapies, including antiangiogenics or
phosphatidylinositol 3-kinase/AKT/mammalian target of
rapamycin pathway inhibitors, have been incorporated into
the treatment armamentarium of GEP-NETs over the past
decade, administered concurrently or sequentially with
SSAs. However, the optimal sequence and timing for the
administration of each of these alternative treatments is
uncertain.11,12 It is hoped that new agents in the pipeline,
such as axitinib, surufatinib, lenvatinib, cabozantinib, and
others, may continue to improve NET management.13
Furthermore, recent progress that has been made in
clarifying the molecular biology of pancreatic NETs—with
the identification of mutated or altered gene expression in
DAXX/ATRX, phosphatidylinositol 3-kinase/Akt/mamma-
lian target of rapamycin, multiple endocrine neoplasia 1,
and other pathways—has provided potential new candi-
dates for targeted therapies.14 In this context of expanding
therapeutic options, a predictive tool of benefit from
treatment with SSAs could be useful for selecting the most
adequate treatment according to individual predicted
benefit,15 as it is already happening in other advanced
tumors.16,17 This model would also inform discussions with
patients in daily practice and assist in the design of future
clinical trials.
The current study aimed to develop and externally vali-
date a predictive model of PFS in patients with advanced,
well-differentiated GEP-NETs treated with SSAs alone.
Furthermore, we investigated the dynamic, nonlinear ef-
fects of Ki-67 percentage in combination with patients’
proinflammatory status on the basis of the neutrophil-to-
lymphocyte ratio.
PATIENTS AND METHODS
Study Population and Design
The model was designed in a training cohort that included
patients from the Spanish National Cancer Registry
(R-GETNE; data cutoff date for analyses was December
2018), a hospital-based registry managed by the Spanish
Group of Neuroendocrine and Endocrine Tumors (GETNE).
This observational registry included consecutive patients who
were diagnosed with GEP-NETs. Its design, characteristics,
and quality criteria have been reported previously.2,18,19
Inclusion criteria for this substudy, GETNE-TRASGU (Treated
With Analog of Somatostatin in Gastroenteropancreatic and
Unknown Primary NETs) consisted of histologic diagnosis of
GEP-NET (pancreas, GI, or unknown origin), advanced
disease measurable by Response Evaluation Criteria in Solid
Tumors (RECIST) version 1.1 andmonitored using computed
tomography at least every 6 months until progression,20 well-
differentiated tumor per WHO 2010 classification with Ki-67
of 20% or less,21 and SSAmonotherapy as first-line treatment
of advanced disease maintained until progression or toxicity.
Eligibility criteria conform to the standard for SSA adminis-
tration for antiproliferative purposes, in accordance with in-
ternational clinical guidelines as well as with regulatory
conditions and clinical practice. Patients who were initially
treated with other systemic treatments or curative surgery for
metastatic disease, or cases with poor documentation of
clinical information were excluded. Sixty centers from across
the country participated in R-GETNE, and data from a total of
3,971 registered patients were screened for eligibility with
additional data quality check—double checking all variables
of interest, monitoring for discrepancies and missing data,
and using multiple filters and controls so as to minimize
unjustified loss of data.
Results were externally validated in a separate cohort from
The Christie NHS Foundation Trust (Manchester, United
Kingdom), which included consecutive patients who met
inclusion criteria and for whom all items included in the
nomogram were available. Any patients with missing in-
formation, including blood results at the time of SSA ini-
tiation, were excluded.
All procedures followed were in accordance with the ethical
standards of the responsible committee on human
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research (institutional and national) and with the Helsinki
Declaration of 1964 and later versions. Informed consent, if
applicable depending on the participating institution, was
obtained from all patients before they were included in
the study.
Objectives and Variables of Interest
The main end point of this study was PFS, which was
defined as the interval of time between commencing SSA
therapy and tumor progression or all-cause mortality,
censoring patients who were lost to follow-up. The aim of
the study was to develop and externally validate a model
enabling patients with GEP-NET to be stratified on the basis
of the length of PFS. Candidate predictors were initially
chosen after a review of the literature and consulting with
GETNE experts. Demographic (age and sex), family
(multiple endocrine neoplasia 1 and other familial syn-
dromes), clinical (body mass index, Eastern Cooperative
Oncology Group performance status, and comorbidities),
documented progression status before initiating SSA (tu-
mor progression, stable disease not documented or , 3
months, and stable disease for$ 3months), tumor (uptake
on scintigraphy with octreotide, clinical status at SSA
treatment initiation, functionality, hepatic tumor burden,
number of organs affected, and sites of metastases), his-
topathologic (Ki-67 percentage, histologic differentiation,
primary tumor site), and laboratory (alkaline phosphatase,
bilirubin, albumin, lactate dehydrogenase, chromogranin
A, 5-hydroxyindoleacetic acid, neutrophil-lymphocyte ratio
[NLR], hemoglobin, and platelets) variables were included.
Statistics
Time-varying, nonlinear effects were explored using sur-
vival analysis with generalized additive models,22,23 repre-
sented as three-dimensional surfaces and contour maps.
No data-driven method was used in the final selection of
variables.24 We performed a redundancy analysis with
flexible parametric additive models to eliminate any co-
variate that could be predicted by the remaining variables.
To examine PFS, we used a log-normal accelerated failure
time (AFT) model, given the nonproportionality of haz-
ards.25 In AFT models, survival times are multiplied by
a constant effect under this formulation such that the
exponentiated coefficients, exp(b), are referred to as time
ratios (TRs). A TR of more than 1 for the covariate implies
that this slows or prolongs the time to event, whereas a TR
of less than 1 indicates that an event is more likely to occur
earlier. Thus, the regression coefficient of a binary predictor
equal to log(0.5) means that the median of time to event is
halved in its presence. Time was measured as a continuous
variable and is expressed in months.
We checked the adequacy of the log-normal parametric
model by computing the Kaplan-Meier estimate of the
distribution of residuals against the theoretical Gaussian
one. Nonlinear effects were modeled by restricted cubic
splines. Variables with more than 20% missing data were
TABLE 1. Baseline Patient Characteristics
Characteristic
TRASGU Training
Cohort
TRASGU Validation
Cohort
R-GETNE
(n = 438)
Christie Hospital
Cohort (n = 97)
Median age, years
(range)
62 (26-89) 64 (26-86)
Sex, female 205 (46.8) 48 (49.4)
Median Ki-67, %
(range)
4 (0-20) 2 (1-20)
Missing values 1 0
Median neutrophils
(range)
3,800 (290-22,000) 4,100 (1,700-13,470)
Missing values 45 0
Median lymphocytes
(range)
1,700 (110-26,400) 1,400 (300-3,400)
Missing values 56 0
Alkaline phosphatase
Normal 272 (62.1) 67 (69.0)
1.1-2.5 ULN 90 (20.5) 23 (23.7)
. 2.5 ULN 40 (9.1) 7 (7.2)
Missing values 36 (8.2) 0
SSA
Sandostatin LAR,
mg
215 (49.1) 50 (51.5)
30 165 (77.7) 48 (96.0)
20 45 (20.9) 1 (2.0)
10 1 (0.4) 1 (2.0)
Missing values 3 (1.3) 0
Lanreotide Autogel,
mg
223 (50.9) 47 (48.4)
120 186 (83.4) 45 (95.8)
90 24 (10.7) 1 (2.1)
60 10 (4.4) 1 (2.1)
Missing values 3 (1.3) 0
Primary tumor site
Small intestine 174 (40.0) 67 (69.1)
Pancreas 166 (37.9) 11 (11.3)
Unknown 43 (9.8) 12 (12.3)
Rectum 22 (5.0) 3 (3.1)
Colon 19 (4.3) 4 (4.1)
Stomach 7 (1.6) 0
Appendix 6 (1.4) 0
Median time from
diagnosis of
metastasis to the
beginning
of SSA treatment,
months (range)
2.0 (0-84) 2.9 (0.4-72.3)
(continued on following page)
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eliminated—for example, mitosis, chromogranin A, and
5-hydroxyindoleacetic acid. Remaining missing data were
then imputed by predictive mean matching.26 The Data
Supplement provides an at-a-glance plot of the pattern of
missing data in the data set. Regarding sample size, the
number of predictors was chosen so that there would be at
least 15 events per covariate.24 The model was represented
as a nomogram; calibration curves were plotted and dis-
crimination assessed using Harrell’s C-index, which takes
into account the right-censored data. Analyses were per-
formed using R version 3.5.1,27 including the Hmisc, rms,
mgcv, visreg, and pammtools packages.22,28-31
RESULTS
Patients and Treatments
The final GETNE-TRASGU database contained 535
patients—438 from the R-GETNE training cohort and 97
from the external validation subset. Table 1 lists baseline
characteristics of both subsets. Demographic data and
therapies were similar in both cohorts, with the exception of
a higher representation of small bowel primaries (69% v
40%) and a smaller proportion of tumors with confirmed
progression status at the time of SSA initiation (11% v 40%)
in the external validation cohort (v the R-GETNE training
set). In the R-GETNE training cohort, a median of 21 doses
of SSA were administered (range, one to 168 doses).
Treatment was initiated at antiproliferative doses in 77%
(octreotide long-acting release 30 mg every 4 weeks) and
83% (Lanreotide Autogel 120 mg every 4 weeks; Ipsen,
Paris, France) of patients. Dose was increased during
follow-up in 14% of cases starting at lower dose; in no case
was it decreased. SSA was discontinued for more than
1 month in only 3.6% of patients. In both cohorts, ap-
proximately half of participants received Lanreotide Autogel
and the other half octreotide long-acting release as SSA
treatment.
Outcomes
Three-hundred progression events were recorded in the
R-GETNE training cohort, with a median follow-up of
33.1 months in patients who did not experience progres-
sion (95% CI, 30.1 to 36.3 months). Median PFS and OS
were 28.7 months (95% CI, 23.8 to 31.1 months) and
85.9 months (95% CI, 71.5 to 96.7 months), respectively.
Curves for both PFS and OS in the R-GETNE cohort have
been incorporated into the Data Supplement. Fifty pro-
gression events were detected in the external valida-
tion series, with median follow-up and PFS values of
31.5 months (95% CI, 15.9 to 41.9 months) and
29.0 months (95% CI, 20.9 to 50.1 months), respectively.
Median OS was not reached.
Development of a Predictive Model of PFS
Both the NLR and Ki-67 percentage index had a pro-
nounced time-varying effect that rapidly faded over time.
The hazard ratio surface and the corresponding contour
map for Ki-67 percentage are illustrated in Figures 1A and
1B. In the case of Ki-67 percentage, the effect was clearly
nonlinear (P = .030) and found to be the predictor that
correlated most closely with PFS (Somers’ Dxy rank cor-
relations in the Data Supplement). For example, the model
illustrates that the residual effect of a Ki-67 percentage of
20% after 20 months of follow-up is approximately
equivalent to the effect of a Ki-67 percentage of 7%
evaluated at time zero, which must be determined if we are
to clarify the true effect of Ki-67 percentage as a predictor of
PFS. In contrast, no clear evidence of nonlinearity was
detected for NLR (Figs 1C and 1D; P = .420).
The log-normal parametric survival time model adequately
fitted the data to the most relevant prognostic factors (Data
Supplement). Nine covariates were significantly associated
with PFS: primary tumor site, Ki-67 percentage, NLR, al-
kaline phosphatase, percentage of hepatic tumor load,
presence of bone and peritoneal metastases, documented
progression status, and presence of symptoms at the time
of the initiation of SSA therapy. No redundancy or in-
teraction between covariates was detected.
TABLE 1. Baseline Patient Characteristics (continued)
Characteristic
TRASGU Training
Cohort
TRASGU Validation
Cohort
R-GETNE
(n = 438)
Christie Hospital
Cohort (n = 97)
Documented progression
status before SSA
Tumor progression 179 (40.8) 11 (11.3)
Stable disease ND or
, 3 months
216 (49.3) 80 (82.4)
Stable disease for
$ 3 months
43 (9.8) 6 (6.1)
Functioning tumor 120 (27.3) 39 (40.2)
Metastasis site
Liver 376 (85.8) 78 (80.4)
Lymph nodes 153 (34.9) 76 (78.3)
Peritoneum 85 (19.4) 21 (21.6)
Bone 38 (8.7) 12 (12.3)
Lung 24 (5.5) 8 (8.2)
Other 24 (5.5) 6 (6.1)
Median No. of organs
involved (range)
1 (1-6) 2 (1-4)
Octreotide scan,
performed
389 (88.8) 84 (86.7%)
Positive 353 (90.7) 78 (92.8%)
NOTE. Data are given as No. (%), unless otherwise noted.
Abbreviations: LAR, long-acting release; ND, not documented; R-GETNE,
Spanish Group of Neuroendocrine and Endocrine Tumors Registry; SSA,
somatostatin analog; TRASGU, Treated With Analog of Somatostatin in
Gastroenteropancreatic and Unknown Primary Neuroendocrine Tumors; ULN,
upper limit of normal.
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Estimated PFS time ratios are listed in Table 2 and shown in
Figure 2. An increase in Ki-67 percentage from 2% to 8%
decreased median PFS by 36% (95% CI, 18% to 49%).
The GETNE-TRASGU model had an adequate calibration
(Fig 3A) and fair discrimination ability with a C-index of
0.714 (95% CI, 0.680 to 0.747) in the R-GETNE training
cohort. The final model is graphically represented in
a nomogram (Fig 4) and a Web-based calculator has been
designed (http://www.iricom.es/prognostictools/trasgu). The
underlying equation and example of its use are specified in
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FIG 1. Three-dimensional surface and contour map showing the time-varying effects of Ki-67 percentage and neutrophil-to-lymphocyte ratio (NLR). (A)
Three-dimensional surface plot showing the relation between Ki-67 percentage and time on the y- and x-axes, respectively. The z-axis shows the
contribution of each combination on the hazard ratio for progression-free survival. (B) Contour map that uses a color gradient to visualize the effect of the
combination on the hazard ratio, where the darker shades of blue indicate a decrease and the darker shades of red denote an increase on the hazard ratio.
(C) Three-dimensional surface for NLR. (D) NLR contour map. The plot shows how the prognostic effect of Ki-67 percentage and NLR is diluted if the
patient survives long enough without experiencing tumor progression. The nonlinear effect consists of higher levels of Ki-67 percentage being associated
with a higher risk of progression, although there is a maximum level around 15% at which subsequent increases no longer correlate with greater risk. In
contrast, NLR has a time-varying effect, but in this case the relation with hazard ratio is approximately linear.
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the Data Supplement. The model is capable of capturing
a remarkable prognostic heterogeneity, stratifying patients
according to their risk (Data Supplement).
External Validation
The GETNE-TRASGU nomogram was validated in an in-
dependent series. In this external validation cohort, the
model retained adequate calibration (Fig 3B) and contin-
ued to enable prognosis-based discrimination of patients
with a C-index of 0.732 (95% CI, 0.658 to 0.806). Kaplan-
Meier curves stratified on the basis of 2-year PFS pre-
dictions are presented in the Data Supplement.
DISCUSSION
The current study describes the development and in-
dependent validation of the GETNE-TRASGU PFS pre-
diction tool for its use in individuals diagnosed with
advanced, well-differentiated GEP-NETs starting treat-
ment with SSA. With 536 patients, it is the largest series
published to date with this objective. To our knowledge,
GETNE-TRASGU is the first statistical model to stratify
and make individualized predictions regarding the
prognosis of patients with NETs being treated with
SSAs.9,10 The model has been independently validated in
an external validation sample of consecutive patients,
maintaining an adequate calibration and capacity to
discriminate PFS.
Two of the applicability criteria are particularly noteworthy: the
absence of metastases that can potentially be cured with
surgery or locoregional therapies and the presence of a Ki-67
percentage index of 20% or less. The GETNE-TRASGU
model assigns an estimation of PFS on the basis of the
additive effect of clinical, analytical, and pathologic variables.
All variables included in this nomogram have been studied
previously in GEP-NETs and have a well-known biologic
substrate. They are all established prognostic factors; how-
ever, their predictive ability has not been described before.9
In the phase III PROMID study, median PFS ranged from
4.6months to 29.4months, depending on the extent of liver
involvement.8 Likewise, in the phase III CLARINET trial,
midgut, hindgut, and pancreatic NETs that were treated
with SSA behaved differently, with median PFS of 61.5
months, 55.0 months, and 29.7 months, respectively.7,9
Documented disease progression status before SSA was
a controlled variable in the CLARINET study, which at-
tributed part of the favorable PFS to the fact that 96% of
patients had stable disease at the time of inclusion.9 In an
observational study, Laskaratos et al10 reported that the
antiproliferative effect of SSAs depended on the location
and histologic differentiation of the primary tumor. Both
alkaline phosphatase and NLR have been correlated with
OS in some series of NETs and general tumors.32-34 The
presence of bone metastases is associated with a poor
prognosis in NETs and other neoplasms.35 In the GETNE-
TRASGU model, after controlling for multiple confounding
factors, peritoneal involvement diminished PFS with a TR of
0.63 (95% CI, 0.43 to 0.90). In other series, such an
adverse impact has not been explicitly reported, although
there might be a relationship between peritoneal metas-
tases and NETs that originate from the ileum or from the
appendix, thus confounding those findings.36 The func-
tioning status variable has a highly complex meaning, as it
may correlate with both high tumor burden and histologic
differentiation. Although the previous series exhibited
variable results overall, once Ki-67 percentage and tumor
burden were controlled for and, above all, insulinomas
excluded, available data did not corroborate function-
ality itself as having a favorable effect in this patient
TABLE 2. AFT Model to Predict Progression-Free Survival
AFT Model to Predict Progression-Free
Survival TR (95% CI) P
Ki-67, 8% v 2% 0.64 (0.51 to 0.82) , .001
NLR, 2 v 8 1.45 (1.04 to 2.00) .026
Primary tumor site
Pancreas, gastric Ref —
Small intestine 1.89 (1.45 to 2.46) , .001
Unknown 1.39 (0.95 to 2.04) .088
Colorectal 1.30 (0.88 to 1.91) .174
Hepatic tumor burden, %
No liver metastases Ref —
. 0-24 0.88 (0.64 to 1.21) .451
25-50 0.67 (0.49 to 0.92) .013
. 50 0.54 (0.37 to 0.78) .001
Peritoneal metastases 0.63 (0.47 to 0.84) .002
Bone metastases 0.63 (0.43 to 0.90) .013
Alkaline phosphatase
Normal Ref —
1.1-2.5 ULN 0.84 (0.64 to 1.09) .200
. 2.5 ULN 0.61 (0.41 to 0.91) .015
Documented progression status before
SSA
Tumor progression Ref —
Stable disease , 3 months or not
documented
1.15 (0.91 to 1.44) .224
Stable disease for $ 3 months 1.65 (1.10 to 2.49) .015
Symptoms, asymptomatic 1.57 (1.18 to 2.10) .001
NOTE. Interpretation of adjusted TRs: TR . 1 means that an increase in the
value of the covariate is associated with longer survival; TR , 1 means that an
increase in the value of the covariate is associated with shorter survival. Adjusted
TRs are derived from a multivariable log-normal AFT model and represent its
exponentiated coefficients.
Abbreviations: AFT, accelerated failure time; NLR, neutrophil-to-lymphocyte
ratio; Ref, reference; SSA, somatostatin analog; TR, time ratio; ULN, upper limit of
normal.
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population.37 In the GETNE-TRASGU study, the presence
of both tumor and endocrine symptoms was associated
with a similarly higher risk of disease progression.
In the GETNE-TRASGU study, we chose an AFTmodel with
log-normal distribution, as opposed to the more usual
proportional hazards model. The rationale for this choice is
based on the fact that the Ki-67 percentage effect was the
most heavily weighted variable; however, its importance
gradually faded with prolonged follow-up. Slow growth
exhibited by well-differentiated GEP-NETs that were treated
with SSA—with expectations of PFS sometimes exceeding
60 months—suggests that the decreasing magnitude of
impact of Ki-67 percentage on PFS, as observed here, likely
occurs in other series.7 Consequently, these dynamic ef-
fects should not be dismissed. Our data show that the
formal verification of the assumption of proportionality of
the hazard ratios is essential when studying NETs. In
contrast, analysis of the nonlinear effect of Ki-67 per-
centage indicates that the cutoffs typically applied in the
WHO classification are not compatible with the structure
of these data. Analysis of the categorized histologic grade
therefore entails a substantial loss of information.2 In fact,
categorizing the Ki-67 percentage by cutoffs has no
known biologic basis. As a result, it must clearly be
evaluated as a continuous variable that allows for non-
linear effects.
SD 3 months v SD not documented or < 3 months
PD v SD not documented or < 3 months
Alkaline phosphatase > 2.5 ULN v normal
Alkaline phosphatase 1.1-2.5 ULN v normal
Liver involvement > 50% v 25% to 50%
Liver involvement 1% to 24% v 25% to 50%
No liver metastases v liver involvement 25% to 50%
Unknown v small intestine
Colorectal v small intestine
Pancreas/stomach v small intestine
Truly asymptomatic
Bone metastases
Peritoneal metastases
NLR − 2:8
Ki-67% − 8:2
0.40 0.50 0.60 0.75 1.00
Time Ratios (90%, 95%, 99% CIs)
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FIG 2. Effect of GETNE-TRASGU (Spanish Group of Neuroendocrine and Endocrine Tumors–TreatedWith Analog of
Somatostatin in Gastroenteropancreatic and Unknown Primary Neuroendocrine Tumors) covariates on progression-
free survival. Adjusted time ratios are derived from a multivariable log-normal accelerated failure time model and
represent its exponentiated coefficients (Table 2). Interpretation of the adjusted time ratios (TR): TR. 1 means that
an increase in the value of the covariate is associated with longer survival. TR, 1means that an increase in the value
of the covariate is associated with shorter survival. NLR, neutrophil-to-lymphocyte ratio; PD, progressive disease; SD,
stable disease; ULN, upper limit of normal.
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FIG 3. Calibration curves in the training and validation cohorts. (A) GETNE-TRASGU cohort. (B) Christie Hospital
cohort. Calibration method consisted of obtaining estimates at intervals of the observed values versus model-
predicted values. The term predictedmeans the probability of progression-free survival (PFS) at a fixed point of time,
whereas observed refers to the Kaplan-Meier survival estimate stratified by intervals.
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Some limitations to the GETNE-TRASGU study should be
noted. First, it is based on retrospective data, with the
consequent loss of accuracy that this entails. To diminish
the negative impact of its retrospective design, we
requested that researchers confirm the quality of the data
by monitoring any possible inconsistency. Second, the
chosen end point—researcher-defined PFS—may vary
from centrally reviewed RECIST v1.1-defined PFS reported
in prospective randomized studies.10 We could argue the
appropriateness of the chosen end point with the following.
First, there are well-known limitations of RECIST for GEP-
NETs.38 In addition, researcher-defined PFS may reflect
a more clinically relevant definition of progression to
treatment with the inclusion of information on the need for
alternative therapeutic strategy. The reader must also be
aware that, as prognosis for patients with well-differentiated
NETs is quantified in several years, the number of events is
low, which makes the OS data more uncertain in the long
term. Consequently, estimations entail greater uncertainty
on the curve tails. Insofar as interpretation is concerned,
it must be remembered that the model does not make
a one-off prediction of what will happen to a given patient at
a given point in time, but rather it establishes an estimation
of a covariate-adjusted survival function. Inclusion of the
proposed model as a key stratification factor in future
clinical trials is strongly encouraged for a definitive pro-
spective validation.
In conclusion, the GETNE-TRASGU nomogram is an
evidence-based tool that is based on nine clinical variables
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FIG 4. GETNE-TRASGU (Spanish Group of Neuroendocrine and Endocrine Tumors–Treated With Analog of Somatostatin in Gastroenteropancreatic and
Unknown Primary Neuroendocrine Tumors) nomogram. SSA, somatostatin analog; ULN, upper limit of normal.
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that make it possible to stratify patients with advanced GEP-
NETs according to PFS estimated during SSA treatment.
The GETNE-TRASGU tool can contribute to making
treatment decisions in the individualized management of
GEP-NETs and to provide risk stratification in future clinical
trials with SSA.
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